<DOC>
	<DOCNO>NCT00278330</DOCNO>
	<brief_summary>This phase I trial study side effect best dose flavopiridol give together vorinostat treat patient relapsed refractory acute leukemia chronic myelogenous leukemia refractory anemia . Flavopiridol vorinostat may cause leukemia cell look like normal cell , grow spread slowly . Vorinostat may also stop growth cancer cell block enzymes need cell growth . Giving flavopiridol together vorinostat may effective treatment leukemia refractory anemia .</brief_summary>
	<brief_title>Flavopiridol Vorinostat Treating Patients With Relapsed Refractory Acute Leukemia Chronic Myelogenous Leukemia Refractory Anemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . Determine recommend phase II dose combination flavopiridol vorinostat patient acute leukemia , chronic myelogenous leukemia blast crisis , refractory anemia excess blasts-2 . SECONDARY OBJECTIVES : I . Determine safety , toxicity , tolerability , maximum tolerate dose drug regimen . II . Determine pharmacodynamic clinical anti-leukemic effect drug regimen . III . Correlate leukemia gene expression pattern response patient treat regimen . OUTLINE : This open-label , dose-escalation study flavopiridol . Patients receive flavopiridol IV 1 hour day 1-5 oral vorinostat three time daily day 1-14 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos flavopiridol maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>Diagnosis one following : Relapsed refractory acute leukemia ( acute myeloid leukemia [ AML ] , acute lymphoblastic leukemia [ ALL ] , acute leukemia unclassifiable ) follow least one prior systemic treatment Acute leukemia patient 60 year old ( requirement prior treatment ) Acute leukemia evolve prior myelodysplastic syndrome Chronic myelogenous leukemia ( CML ) blast crisis follow prior imatinib mesylate therapy Refractory anemia excess blasts2 ( RAEB2 ) No know CNS leukemia ECOG performance status 02 WBC &lt; 50,000ÂµL Hydroxyurea and/or leukaphereses may use low WBC Creatinine = &lt; 1.5 time upper limit normal ( ULN ) OR creatinine clearance &gt; = 50 mL/min Total bilirubin = &lt; 2 time ULN AST/ALT = &lt; 2.5 time ULN QTc interval = &lt; 0.470 second Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No condition would preclude study participation At least 3 week since prior treatment ( expect leukaphereses ) No valproic acid therapy within past 2 week No prior autologous allogeneic bone marrow stem cell transplantation No hydroxyurea use within past 24 hour No concurrent treatment anticancer agent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>